Cargando…

Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors

Anti-mPEG/anti-human epidermal growth factor receptor 2 (HER2) bispecific antibodies (BsAbs) non-covalently bound to a docetaxel (DTX)-loaded mPEGylated lecithin-stabilized micellar drug delivery system (L(sb)MDDs) were endowed with active targetability to improve the chemotherapeutic efficacy of DT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Chia-Yu, Chen, Michael, Chen, Ling-Chun, Ho, Yuan-Soon, Ho, Hsiu-O, Lin, Shyr-Yi, Chuang, Kuo-Hsiang, Sheu, Ming-Thau
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058516/ https://www.ncbi.nlm.nih.gov/pubmed/29718725 http://dx.doi.org/10.1080/10717544.2018.1466936

Ejemplares similares

Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy
por: Lin, Wen-Wei, et al.
Publicado: (2021)

Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer
por: Cheng, Wei-Jie, et al.
Publicado: (2022)

Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity
por: Cheng, Wei-Jie, et al.
Publicado: (2021)

Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer
por: Cheng, Yi-An, et al.
Publicado: (2020)

Functionalization of silver nanoparticles with mPEGylated luteolin for selective visual detection of Hg(2+) in water sample
por: Qing, Weixia, et al.
Publicado: (2018)

On-demand PEGylation and dePEGylation of PLA-based nanocarriers via amphiphilic mPEG-TK-Ce6 for nanoenabled cancer chemotherapy
por: Zhu, Yueqiang, et al.
Publicado: (2019)

Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity
por: Ho, Kai-Wen, et al.
Publicado: (2021)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
por: Mohammadi, Mehdi, et al.
Publicado: (2021)

Docetaxel loaded mPEG-PLA nanoparticles for sarcoma therapy: preparation, characterization, pharmacokinetics, and anti-tumor efficacy
por: Chen, Jianhua, et al.
Publicado: (2021)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
por: Yu, Shengnan, et al.
Publicado: (2017)

Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
por: Huang, Sijia, et al.
Publicado: (2018)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

Drug-interactive mPEG-b-PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel
por: Gong, Feirong, et al.
Publicado: (2020)

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities
por: Liu, Jiayu, et al.
Publicado: (2019)

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
por: Schram, Alison M., et al.
Publicado: (2022)

Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
por: Zhuang, Weiliang, et al.
Publicado: (2023)

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
por: Wang, Lei, et al.
Publicado: (2013)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
por: Lum, Lawrence G., et al.
Publicado: (2021)

Targeted delivery by pH-responsive mPEG-S-PBLG micelles significantly enhances the anti-tumor efficacy of doxorubicin with reduced cardiotoxicity
por: Feng, Qiyi, et al.
Publicado: (2021)

Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
por: Zhang, F., et al.
Publicado: (2019)

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
por: Chu, Wendi, et al.
Publicado: (2022)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene
Publicado: (1992)

Synthesis, characterization, and evaluation of mPEG–SN38 and mPEG–PLA–SN38 micelles for cancer therapy
por: Xie, Jing, et al.
Publicado: (2016)

Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies
por: Hollevoet, Kevin, et al.
Publicado: (2018)

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer
por: James, N D, et al.
Publicado: (2001)

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
por: Rau, Alexander, et al.
Publicado: (2021)

A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
por: Li, Aifen, et al.
Publicado: (2016)

Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors
por: Oberg, Hans‐Heinrich, et al.
Publicado: (2019)

PEGylation of lipophilic SN38 prodrug with DSPE-mPEG(2000) versus cremophor EL: comparative study for intravenous chemotherapy
por: Zeng, Jun, et al.
Publicado: (2019)

(99m)Tc-Radiolabeled Silica Nanocarriers for Targeted Detection and Treatment of HER2-Positive Breast Cancer
por: Rainone, Paolo, et al.
Publicado: (2021)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
por: Vaishampayan, Ulka, et al.
Publicado: (2015)

Micellar emulsions composed of mPEG-PCL/MCT as novel nanocarriers for systemic delivery of genistein: a comparative study with micelles
por: Zhang, Tianpeng, et al.
Publicado: (2015)

Efficient Self-Assembly of mPEG End-Capped Porous Silica as a Redox-Sensitive Nanocarrier for Controlled Doxorubicin Delivery
por: Nguyen, Anh Khoa, et al.
Publicado: (2018)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY
por: Kumthekar, Priya, et al.
Publicado: (2023)

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
por: Chen, Yi-Li, et al.
Publicado: (2021)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0mlnapdmcentb71vqe72jlub6t